PositiveReview/Other2016
Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis
Classification Results
AI Classification
PositiveFine-tuned Classification
Positive